 |
 |

Aberrant Tyrosine Transport Across the Cell Membrane in Patients With Schizophrenia
Lena Flyckt, MD;
Nikolaos Venizelos, MD, PhD;
Gunnar Edman, MD, PhD;
Lars Bjerkenstedt, MD, PhD;
Lars Hagenfeldt, MD, PhD;
Frits-Axel Wiesel, MD, PhD
Arch Gen Psychiatry. 2001;58:953-958.
Background There is evidence that patients with schizophrenia exhibit abnormalities,
not only in the brain but also in peripheral organs. An abnormal cell membrane
composition has been suggested to be a common denominator, supported by findings
of alterations in membrane phospholipid levels. In a previous study, the transport
of amino acids across the plasma membrane was investigated with fibroblasts
from patients with schizophrenia and controls. An isolated decrease in the
maximal transport capacity (Vmax) of tyrosine was observed in the
cells from patients. In this context, tyrosine transport across the fibroblast
membrane was investigated in patients with schizophrenia and healthy control
subjects.
Methods Skin fibroblasts were obtained from 36 patients with schizophrenia (15
first episode and 21 chronic) and 10 healthy controls. Tyrosine transport
across the cell membrane was studied in cultivated fibroblasts. The Vmax and the affinity of the tyrosine binding sites (Km) were determined.
Results Significantly lower Vmax (F1,41 = 12.80; P = .001; effect size = 1.36) and Km (F1,41 = 24.85; P<.001; effect
size = 1.00) were observed in fibroblasts from the patients. The findings
were present in both neuroleptic-naive patients with their first episode and
patients with chronic schizophrenia.
Conclusions The lower Vmax and Km
are compatible with a cell membrane disturbance and support the view of schizophrenia
as a systemic disorder. The decreased Vmax and Km observed in cells from schizophrenic patients probably
reflect a genetic trait, as the changes were transmitted through several cell
generations of cultured fibroblast.
From the Division of Psychiatry, Karolinska Institutet, Danderyds Hospital,
Stockholm, Sweden (Drs Flyckt, Edman, and Bjerkenstedt); Center for Inherited
Metabolic Diseases, Karolinska Institutet, Huddinge University Hospital, Stockholm
(Drs Venizelos and Hagenfeldt); and Department of Neuroscience, Psychiatry,
Uppsala University Hospital, Uppsala, Sweden (Dr Wiesel).
Corresponding author and reprints: Lena Flyckt, MD, FoUU, Department
of Psychiatry, Danderyds Hospital, S-18288 Danderyd, Sweden (e-mail:
lena.flyckt{at}kids.ki.se).
|